Research and Markets: Pain Management Therapeutics: A Strategic Market Outlook and Business Analysis.DUBLIN, Ireland -- In 2008, over 4.6 Billion New Cases of Acute Pain Events Will Be Reported Worldwide Research and Markets (http://www.researchandmarkets.com) has announced the addition of Pain Management Therapeutics: A Strategic Market Outlook and Business Analysis to their offering. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. the International Association for the Study of Pain The International Association for the Study of Pain (IASP) is an international professional organisation for doctors and other health professionals involved in the diagnosis, treatment and scientific study of pain, as well as education and training in the field of pain medicine. (IASP IASP International Association for the Study of Pain IASP International Association of Science Parks IASP International Association for Suicide Prevention IASP Information Assurance Scholarship Program IASP Independent Auxiliary Storage Pool ), pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. It is often categorized by the duration of pain and/or mechanism. For the scope of this report, chronic pain is defined, as pain that lasts more than 6 months and acute pain is a condition experienced for less than 6months. Each subcategory sub·cat·e·go·ry n. pl. sub·cat·e·go·ries A subdivision that has common differentiating characteristics within a larger category. of pain is then identified by its localization Customizing software and documentation for a particular country. It includes the translation of menus and messages into the native spoken language as well as changes in the user interface to accommodate different alphabets and culture. See internationalization and l10n. . It is estimated that over 60% of the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. and worldwide population suffers from various types of chronic pain. In 2008, over 4.6 billion new cases of acute pain events will be reported worldwide. Currently, nonsteroidal anti-inflammatory drugs Nonsteroidal Anti-Inflammatory Drugs Definition Nonsteroidal anti-inflammatory drugs are medicines that relieve pain, swelling, stiffness, and inflammation. and narcotics narcotics n. 1) techinically, drugs which dull the senses. 2) a popular generic term for drugs which cannot be legally possessed, sold, or transported except for medicinal uses for which a physician or dentist's prescription is required. are used as primary therapeutics for mild and severe pain; however, other drug classes such as antimigraine agents and ion flux inhibitors are in use as well. Front Line expects the emerging pain management market to experience significant growth to 2008. Factors that affect both volume and price growth will have an overall positive influence on novel drug adoption, with the first new drug expected to reach the market in 2003. New classes of drugs entering the market include: ion flux inhibitors, neurotoxins, CNS See Continuous net settlement. CNS See continuous net settlement (CNS). drugs, NMDA antagonists, radiopharmaceuticals, and tetraphosphanate chelating agents chelating agents (kē`lātĭng). Certain organic compounds are capable of forming coordinate bonds (see chemical bond) with metals through two or more atoms of the organic compound; such organic compounds are called chelating agents. . Projected revenue from emerging therapeutics is expected to reach $6.1 billion in 2008. Therapeutics for a thorough analysis of this high-growth market, this report: - Assesses the market potential of emerging pain management products currently in development - Includes clinical development status, safety and efficacy results, mechanism of action, market attractiveness, and company specific data - Projects launch dates of phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA and later drugs - Estimates first-year and 2008 revenue of upcoming therapeutics - Includes analysis of future market influences and identification of unmet needs in the pain management marketA Report Contents: I. Executive Summary - A. Overview - B. Scope - C. Definition - D. Therapeutics - E. Chronic and Acute Pain Prevalence and Incidence - F. Pain Management Market Revenues (2003E - 2008E) - G. Segment Revenues (2003E and 2008E) - H. Competitive Environment (2003E and 2008E) - I. Emerging Therapeutics - J. Market Influencing Factors - K. Strategic Analysis II. Objectives and Methodology - A. Report Objectives and Scope - B. Methodology - C. Data Collection - D. Strategic Recommendations - III. Pain Management Clinical Overview - A. Definition - B. Neurobiology Neurobiology Study of the development and function of the nervous system, with emphasis on how nerve cells generate and control behavior. The major goal of neurobiology is to explain at the molecular level how nerve cells differentiate and develop their of Pain - C. Causes and Risk Factors - D. Implications of Pain in Diagnosis and Prognosis - E. Chronic and Acute Pain Prevalence and Incidence IV. Current Treatments - A. Therapeutics - B. Physical Therapies - C. Behavioral Therapies - D. Emerging Treatments V. Emerging Pain Management Therapeutics - A. Overview - B. Products in Development Analysis Methodology - C. Products in Phase III or Later - D. Compounds in Phase II - E. Compounds in Phase I - F. Compounds in Pre-Clinical Development Pre-clinical development is a stage in the development of a new drug that begins before clinical trials (testing in humans) can begin, and during which important safety and pharmacology data is collected. - G. Company Analysis 1. aaiPharma 2. Allergan 3. ALZA (J&J Subsidiary) 4. Amarin 5. Biovail 6. Bristol-Myers Squibb 7. Dainippon 8. DURECT 9. Elan 10.Endo 11.Forest 12.GlaxoSmithKline 13.GW 14.Labopharm 15.Mallinckrodt (Tyco Subsidiary) 16.Novartis 17.Pfizer 18.POZEN 19.Purdue 20.Shionogi 21.SkyePharma 22.Takeda 23.Vyteris VI. Pain Management Market - A. Pain Management Market Revenues (2003E-2008E) - B. Segment Revenues (2003E and 2008E) - C. Competitive Environment (2003E and 2008E) - D. Company Profiles - E. Top Worldwide Product Sales (2003E - 2008E) - F. Emerging Therapeutics - G. Market Model Construction VII. Market Influencing Factors - A. Overview - B. Factors in the Pain Management Market VIII. Strategic Analysis - A. Overview - B. Evaluate the Near-Term Industry Landscape - C. Identify Market Opportunities - D. Form Strategic Options Appendix: - A. Definitions - B. Acronyms For more information visit http://www.researchandmarkets.com/reports/c4786 |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion